CWA Asset Management Group LLC Buys Shares of 21,961 InMode Ltd. (NASDAQ:INMD)

CWA Asset Management Group LLC bought a new position in shares of InMode Ltd. (NASDAQ:INMD) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 21,961 shares of the healthcare company’s stock, valued at approximately $367,000.

Other institutional investors also recently modified their holdings of the company. Systematic Financial Management LP grew its position in InMode by 13.3% during the 3rd quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company’s stock worth $16,647,000 after acquiring an additional 115,492 shares during the last quarter. Barclays PLC boosted its stake in shares of InMode by 113.5% during the third quarter. Barclays PLC now owns 169,630 shares of the healthcare company’s stock valued at $2,876,000 after purchasing an additional 90,173 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of InMode by 54.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,480 shares of the healthcare company’s stock worth $2,127,000 after purchasing an additional 44,058 shares during the last quarter. Hsbc Holdings PLC increased its stake in shares of InMode by 129.7% in the second quarter. Hsbc Holdings PLC now owns 90,280 shares of the healthcare company’s stock valued at $1,659,000 after buying an additional 50,974 shares during the period. Finally, State Street Corp raised its holdings in InMode by 3.7% in the 3rd quarter. State Street Corp now owns 2,044,640 shares of the healthcare company’s stock valued at $34,657,000 after buying an additional 73,183 shares during the last quarter. 68.04% of the stock is currently owned by institutional investors and hedge funds.

InMode Stock Performance

NASDAQ:INMD opened at $16.01 on Thursday. InMode Ltd. has a 52 week low of $14.87 and a 52 week high of $26.80. The firm’s fifty day moving average is $18.11 and its 200-day moving average is $17.32. The firm has a market cap of $1.34 billion, a P/E ratio of 8.65 and a beta of 2.12.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Barclays reduced their target price on shares of InMode from $29.00 to $27.00 and set an “overweight” rating on the stock in a report on Monday, October 14th. BTIG Research initiated coverage on shares of InMode in a research note on Thursday, October 17th. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, Needham & Company LLC restated a “hold” rating on shares of InMode in a report on Thursday, October 31st. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, InMode presently has an average rating of “Hold” and a consensus target price of $22.60.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.